Daina Graybosch

Stock Analyst at Leerink Partners

(0)
# 4667
Out of 5,329 analysts
132
Total ratings
28.41%
Success rate
-19.98%
Average return
21 Stocks
Name Action PT Current % Upside Ratings Updated
TSVT 2seventy bio
Downgrades: Market Perform
9 5
5 0% 6 Mar 11, 2025
MRK Merck & Co
Maintains: Outperform
136 119
83.59 42.36% 19 Jan 13, 2025
LVTX LAVA Therapeutics
Downgrades: Market Perform
11 2
1.26 58.73% 6 Dec 12, 2024
BOLT Bolt Biotherapeutics
Downgrades: Market Perform
3 1
0.36 177.78% 8 May 15, 2024
ACLX Arcellx
Maintains: Outperform
35 39
66.03 -40.94% 5 Mar 30, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
5 3
0.76 294.74% 10 Feb 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
20 14
0.55 2445.45% 4 Jan 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
62 10
1.29 675.19% 7 Jan 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
100 60
0.97 6085.57% 7 Dec 12, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
10 9
2.27 296.48% 10 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
40 38
8.96 324.11% 2 Nov 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
30 8
3.75 113.33% 4 Aug 29, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
223 224
105.4 112.52% 16 Jul 29, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
30
2.06 1356.31% 1 Jul 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
21 7
n/a n/a 4 Jun 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
60 59
7.65 671.24% 7 May 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
18 17
0.9 1788.89% 3 May 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
25 2
n/a n/a 6 Apr 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
16 9
1.53 488.24% 4 Feb 25, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
5 6
n/a n/a 2 Apr 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
68
n/a n/a 1 Dec 11, 2019